Neuralstem, Inc. is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. The Company has developed and maintain a portfolio of patents and patent applications that form the base of its research and development efforts in the areas of neural stem cell research, small molecule research, and related technologies.
04/10/11Neuralstem shares jump over 13% on new stem cell patent
16/12/10Neuralstem Receives FDA Approval to Start Phase Ia Trial for Depression Drug
14/09/10Study Shows Neuralstem’s Stem Cells May Have Application To Treating Stroke
Recent Sector News
U.S. stocks ended higher Thursday, with the Dow given a big lift by Visa as well as upbeat economic data, a day after the Fed showed confidence in the US economy and pulled the plug on its latest quantitative easing program.
Supreme says rejection of South Okanagan marijuana facility a short-term setback, remains focused on flagship Kincardine site
Due to strong support from the local community, Supreme has been able to move quickly to implement its proposed plan to produce up to 24 million grams of medical marijuana from Kincardine, for which it received conditional pre-approval from Health Canada in January.
ProMetic Life Sciences (TSE:PLI)(OTCQX:PFSCF) rallied today after the FDA cleared the company's investigational new drug application and clinical trial program for its IV plasminogen to treat plasminogen deficiency.
Canadian biopharmaceuticals firm Tekmira Pharmaceuticals (NASDAQ:TKMR) (TSE:TKM) jumped in early deals Wednesday after the company said it has begun limited manufacturing of a new therapeutic targeting the Ebola-Guinea virus, which is the viral variant responsible for the current epidemic in West Africa.
Tekmira's (NASDAQ:TKMR) (TSE:TKM) shares have been rising this week ever since the first US case of Ebola emerged in Texas, and are up another 8 percent today after announcing a $1.5 million milestone payment from agricultural giant Monsanto (NYSE:MON).
OrganiGram (CVE:OGI) is currently one of 13 licensed producers for medical marijuana so far in Canada under the government’s new regulations, but the company is the only provider east of Ontario and one of two producers (the sole publicly listed one) growing an organic product.
Investors interested in Neuralstem recently viewed
- ReNeuron (AIM: RENE) Leading stem cell company targeting areas of significant unmet medical need
- Clinigen Group PLC (AIM: CLIN) .
- Horizon Discovery Group (AIM: HZD) .
- ImmuPharma PLC (AIM: IMM) Drug Discovery & Development to Treat Lupus, Cancer & MRSA
- Oxford Pharmascience (AIM: OXP) Developing proprietary delivery systems for medicines & supplements